Begins Coverage on Trevena (NASDAQ:TRVN)

Equities research analysts at began coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

NASDAQ TRVN opened at $0.60 on Tuesday. The business’s 50-day moving average price is $0.63 and its 200 day moving average price is $0.87. Trevena has a twelve month low of $0.51 and a twelve month high of $3.93. The company has a market capitalization of $8.21 million, a PE ratio of -0.13 and a beta of 1.80. The company has a current ratio of 4.03, a quick ratio of 3.92 and a debt-to-equity ratio of 1.45.

Trevena (NASDAQ:TRVNGet Free Report) last released its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.24). The company had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.70 million.

Institutional Investors Weigh In On Trevena

A number of large investors have recently modified their holdings of TRVN. Millennium Management LLC acquired a new position in shares of Trevena in the 2nd quarter worth approximately $808,000. Renaissance Technologies LLC grew its position in shares of Trevena by 222.4% in the 2nd quarter. Renaissance Technologies LLC now owns 994,200 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 685,800 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Trevena in the 4th quarter worth approximately $919,000. Captrust Financial Advisors lifted its holdings in shares of Trevena by 10,526.3% in the 1st quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Trevena in the 2nd quarter worth approximately $70,000. Institutional investors and hedge funds own 4.95% of the company’s stock.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Recommended Stories

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.